Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
1990 1
1991 2
1993 1
1994 2
1995 1
1996 1
1998 1
1999 1
2000 2
2001 4
2002 3
2003 1
2004 1
2005 4
2006 3
2008 2
2009 2
2011 3
2012 2
2013 1
2014 2
2015 4
2016 2
2017 2
2018 6
2019 6
2020 2
2021 7
2022 5
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.
Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Ferreli C, et al. Clin Rev Allergy Immunol. 2017 Dec;53(3):306-336. doi: 10.1007/s12016-017-8625-4. Clin Rev Allergy Immunol. 2017. PMID: 28712039 Review.
Scleroderma refers to an autoimmune connective tissue fibrosing disease, including three different subsets: localized scleroderma, limited cutaneous systemic sclerosis, and diffuse cutaneous systemic sclerosis with divergent patterns of organ involveme …
Scleroderma refers to an autoimmune connective tissue fibrosing disease, including three different subsets: localized scleroderma, limite …
Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study(,,,).
Lescoat A, Murphy SL, Chen YT, Vann N, Galdo FD, Cella D, Buch MH, Khanna D. Lescoat A, et al. Semin Arthritis Rheum. 2022 Feb;52:151926. doi: 10.1016/j.semarthrit.2021.11.003. Epub 2021 Nov 7. Semin Arthritis Rheum. 2022. PMID: 34785028 Free PMC article.
OBJECTIVES: Limited cutaneous systemic sclerosis (lcSSc) is the largest subgroup of people with SSc, but little is known about symptom experience from the patients' perspective. ...
OBJECTIVES: Limited cutaneous systemic sclerosis (lcSSc) is the largest subgroup of people with SSc, but little …
Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity.
Favoino E, Grapsi E, Barbuti G, Liakouli V, Ruscitti P, Foti C, Giacomelli R, Perosa F. Favoino E, et al. Clin Exp Immunol. 2023 Apr 7;212(1):32-38. doi: 10.1093/cei/uxad012. Clin Exp Immunol. 2023. PMID: 36715304 Free PMC article.
Anti-centromere (ACA) and antimitochondrial antibodies (AMA) are specific for limited-cutaneous systemic sclerosis (lcSSc) and primary biliary cholangitis (PBC), respectively, and can coexist in up to 25 and 30% of SSc and PBC patients. ...
Anti-centromere (ACA) and antimitochondrial antibodies (AMA) are specific for limited-cutaneous systemic sclerosis …
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold AM, Kuwana M, Merkel PA, Stock C, Sambevski S, Denton CP; SENSCIS Trial Investigators. Allanore Y, et al. Rheumatology (Oxford). 2024 Mar 1;63(3):639-647. doi: 10.1093/rheumatology/kead280. Rheumatology (Oxford). 2024. PMID: 37294870 Free PMC article. Clinical Trial.
OBJECTIVES: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomized to receive ninted …
OBJECTIVES: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cu …
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, Khanna D. Lescoat A, et al. Clin Rev Allergy Immunol. 2023 Jun;64(3):239-261. doi: 10.1007/s12016-021-08891-0. Epub 2021 Sep 1. Clin Rev Allergy Immunol. 2023. PMID: 34468946 Free PMC article. Review.
Two major subsets of systemic sclerosis are classically described: limited cutaneous systemic sclerosis characterized by distal skin fibrosis and the diffuse subset with distal and proximal skin thickening. ...
Two major subsets of systemic sclerosis are classically described: limited cutaneous systemic sclerosis characte …
Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.
Fett N. Fett N. Clin Dermatol. 2013 Jul-Aug;31(4):432-437. doi: 10.1016/j.clindermatol.2013.01.010. Clin Dermatol. 2013. PMID: 23806160 Review.
The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the current …
The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous …
The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort.
Hernández J, Jordan S, Dobrota R, Iudici M, Hasler P, Ribi C, Villiger P, Vlachoyiannopoulos P, Vacca A, Garzanova L, Giollo A, Rosato E, Kötter I, Carreira PE, Doria A, Henes J, Müller-Ladner U, Smith V, Distler J, Gabrielli A, Hoffman-Vold AM, Walker U, Distler O; The Eustar Collaborators. Hernández J, et al. Swiss Med Wkly. 2021 Jul 14;151:w20528. doi: 10.4414/smw.2021.20528. eCollection 2021 Jul 5. Swiss Med Wkly. 2021. PMID: 34283895 Free article.
Despite the earlier referral of Swiss patients to systemic sclerosis expert centres, they showed evidence of more severe disease, particularly in the limited cutaneous systemic sclerosis subset, but no differences in overall survival on longitudinal fo …
Despite the earlier referral of Swiss patients to systemic sclerosis expert centres, they showed evidence of more severe disease, particular …
Disease progression and changes in KL-6 in patients with limited cutaneous systemic sclerosis-associated interstitial lung disease.
Takei R, Yamano Y, Kataoka K, Fukihara J, Sasano H, Yokoyama T, Matsuda T, Kimura T, Kondoh Y. Takei R, et al. Respir Investig. 2024 Jan;62(1):44-48. doi: 10.1016/j.resinv.2023.09.003. Epub 2023 Nov 7. Respir Investig. 2024. PMID: 37944381
BACKGROUND: Little is known about the annual change in Krebs von Lungen-6 (KL-6) and its correlation with forced vital capacity (FVC) in limited cutaneous systemic sclerosis-associated interstitial lung disease (lcSSc-ILD). ...
BACKGROUND: Little is known about the annual change in Krebs von Lungen-6 (KL-6) and its correlation with forced vital capacity (FVC) in …
Systemic sclerosis sine scleroderma and limited cutaneous systemic sclerosis: similarities and differences.
Simeón-Aznar CP, Tolosa-Vilella C, Gabarró-Juliá L, Campillo-Grau M, Guillén Del Castillo A, Fonollosa-Plá V, Vilardell-Tarrés M. Simeón-Aznar CP, et al. Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-33-40. Epub 2014 Apr 28. Clin Exp Rheumatol. 2014. PMID: 24776173
OBJECTIVES: To compare a cohort of patients with systemic sclerosis sine scleroderma (ssSSc) vs. patients with limited cutaneous systemic sclerosis (lcSSc). METHODS: Forty-five patients with ssSSc and 186 patients with lcSSc were investigated. ...
OBJECTIVES: To compare a cohort of patients with systemic sclerosis sine scleroderma (ssSSc) vs. patients with limited cutaneous …
74 results